Evidence map›Paper›PMID 39310954›Full record

ArticleNanoscale2024

Assessing the conjugation efficiency of surface-modified extracellular vesicles using single nanovesicle analysis technologies.

Leora Goldbloom-Helzner, Harjn Bains, Emma G Loll, Tanner Henson, Rachel R Mizenko, Priyadarsini Kumar, Cheemeng Tan, Diana L Farmer, Randy P Carney, Aijun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Leora Goldbloom-HelznerCenter for Surgical Bioengineering, Department of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA. aawang@ucdavis.edu.
Harjn BainsDepartment of Biomedical Engineering, University of California-Davis, Davis, CA, 95616, USA.
Emma G LollCenter for Surgical Bioengineering, Department of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA. aawang@ucdavis.edu.ORCID http://orcid.org/0009-0005-7021-4025
Tanner HensonCenter for Surgical Bioengineering, Department of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA. aawang@ucdavis.edu.
Rachel R MizenkoDepartment of Biomedical Engineering, University of California-Davis, Davis, CA, 95616, USA.
Priyadarsini KumarCenter for Surgical Bioengineering, Department of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA. aawang@ucdavis.edu.
Cheemeng TanDepartment of Biomedical Engineering, University of California-Davis, Davis, CA, 95616, USA.
Diana L FarmerCenter for Surgical Bioengineering, Department of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA. aawang@ucdavis.edu.
Randy P CarneyDepartment of Biomedical Engineering, University of California-Davis, Davis, CA, 95616, USA.ORCID http://orcid.org/0000-0001-8193-1664
Aijun WangCenter for Surgical Bioengineering, Department of Surgery, School of Medicine, University of California-Davis, Sacramento, CA, 95817, USA. aawang@ucdavis.edu.ORCID http://orcid.org/0000-0002-2985-3627

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Engineering and dissecting the synthetic non-dividing-but-active state of hybrid cell-materialsR35GM142788 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Cheemeng Tan · 2021 to 2026
$2.7M
Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida TherapyR01NS115860 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FARMER, DIANA LEE, WANG, AIJUN · 2020 to 2024
$2.5M
Bottom-up, high-throughput prototyping of extracellular vesicle mimetics using cell-free synthetic biologyR01EB034279 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Randy Carney, Cheemeng Tan · 2023 to 2026
$2.5M
Homogenized, engineered extracellular vesicles for intracranial targetingR01EB033389 · NIBIB · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Randy Carney, Aijun Wang · 2023 to 2026
$2.4M
Engineering an extracellular vesicle-based targeted regenerative nanotherapeutic for multiple sclerosisR01NS131538 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aijun Wang · 2024 to 2026
$1.4M
UC Davis Shared Astrios Cell SorterS10OD018223 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHACKLETT, BARBARA L. · 2015 to 2015
$555k
NCI NIH HHS P30 CA093373NIBIB NIH HHS R01 EB033389NIBIB NIH HHS R01 EB034279NIH HHS S10 OD018223NINDS NIH HHS R01 NS115860NINDS NIH HHS R01 NS131538
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are cell-secreted nanoscale vesicles with important roles in cell-cell communication and drug delivery. Although EVs pose a promising alternative to cell-based therapy, targeted delivery

Indexed as

Aptamers, NucleotideExtracellular VesiclesHumansMyelin SheathSurface PropertiesAptamers, Nucleotide

Identifiers

PMID39310954
PMCPMC11748815

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.